Robert E. Hoffman Kintara Therapeutics, Inc. (KTRA) insider trading activity

KTRA Quotes by TradingView

Robert E. Hoffman is President, CEO and Interim CFO of Kintara Therapeutics, Inc.. Currently has a direct ownership of 68,902 shares of KTRA, which is worth approximately $12,402. The most recent transaction as insider was on Jun 01, 2023, when has been sold 59,800 shares (Common Stock, par value $0.001 per share) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 68.9K
0% 3M change
0% 12M change
Total Value Held $12,402

Robert E. Hoffman Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 01 2023
BUY
Grant, award, or other acquisition
-
59,800 Added 46.46%
68,902 Common Stock, par valu...
Aug 01 2022
BUY
Grant, award, or other acquisition
-
400,145 Added 46.78%
455,145 Common Stock
Feb 15 2022
BUY
Open market or private purchase
$25,850 $0.47 p/Share
55,000 Added 50.0%
55,000 Common Stock

Also insider at

KURA
Kura Oncology, Inc. Healthcare
Director
FBLG
FibroBiologics, Inc.
Director
REH

Robert E. Hoffman

President, CEO and Interim CFO
San Diego, CA

Track Institutional and Insider Activities on KTRA

Follow Kintara Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KTRA shares.

Notify only if

Insider Trading

Get notified when an Kintara Therapeutics, Inc. insider buys or sells KTRA shares.

Notify only if

News

Receive news related to Kintara Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on KTRA